shutterstock_713156257_-jacob-lund
Jacob Lund / Shutterstock.com
20 May 2019EuropeMichael Pears and Joel Beevers

SPCs: extending protection lifespan

Supplementary protection certificates (SPCs) are intended to ensure that medicinal products requiring marketing authorisation (MA) are adequately protected. They safeguard a sufficient return for, and thereby incentivise, pharmaceutical research involving significant pre-clinical and clinical work. Such work can include not only the development of new active ingredients per se, but also new inventions involving existing active ingredients.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
2 June 2026   The court has officially opened its mediation and arbitration forum, with technology, life sciences and manufacturing companies expected to be among its earliest users—particularly in FRAND and licensing cases.
Europe
28 May 2026   A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.
Europe
21 May 2026   The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.